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Dengue virus (DENV) continues to spread globally and is a major cause of morbidity and
mortality. Currently, there is no antiviral treatment to diminish severe illness or a vaccine to
induce protection from infection. An effective dengue vaccine that protects against all four
DENV serotypes is a high priority for endemic countries and several candidates are in devel-
opment by various United States Federal Agencies and private pharmaceutical companies.
Challenges faced by dengue vaccine developers include creating tetravalent formulations
that provide tetravalent protection, the lack of a correlate of protective immunity, a chang-
ing viral landscape as DENV evolves, and a complex viral-host pathogenesis that can result
in a spectrum of illness from subclinical infection to severe hemorrhagic fever. There have
been a number of long-term prospective studies on DENV transmission and dengue sever-
ity that have provided invaluable information on DENV epidemiology and pathogenesis of
this disease. In this section, we will review the critical lessons learned from these studies
and their application for dengue vaccine development.
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INTRODUCTION
The global dengue pandemic and its associated morbidity and
mortality have been covered in other excellent reviews and sections
of this textbook and will not be reviewed here. Prospective studies
have been a valuable tool in understanding the epidemiology and
pathogenesis of dengue virus (DENV) infection. For the dengue
vaccine developer specifically these studies offer the advantage of
determining the true incidence of infection, the full spectrum of
clinical outcomes from subclinical to severe hospitalized illness,
risk factors for disease severity, and viral information on the genet-
ics and evolution of DENV and its spatial and temporal spread.
Recently, the results of a Phase 2b candidate tetravalent DENV
vaccine [yellow fever (YF)-dengue chimeric, Sanofi Pasteur] were
published (1). This was conducted in a highly flavivirus antibody
experienced cohort of children in Thailand and demonstrated an
excellent safety and neutralizing antibody immunogenicity profile.
The vaccine however, failed to achieve protection against all four
DENV types with an overall efficacy of 30.2%. Efficacy varied by
DENV type with the lowest noted against DENV-2 (9.2%), which
was the predominant circulating DENV serotype at the time of
the trial. The results of this efficacy trial highlighted several devel-
opment challenges for a dengue vaccine including the lack of a
correlation of protection despite the detection of serotype-specific
neutralizing antibody.
In this section, the lessons learned from the prospective cohort
studies and their application to DENV vaccine development will
be reviewed. Though much information has been learned from
these important studies, there are six important lessons learned
Abbreviations: DENV, dengue virus; DF, dengue fever; DHF, dengue hemorrhagic
fever; NAb, neutralizing antibody; PRNT, plaque reduction neutralizing titer.
that I believe are critical for DENV vaccines and include: (1)
incidence rates will support Phase III efficacy studies though a
high degree of temporal and spatial diversity in incidence occurs
requiring consideration in choosing populations; (2) demonstra-
tion that pre-existing serotype-specific neutralizing antibody does
not protect against infection suggests that our current assays to
measure neutralizing antibody are not a correlate for protection;
(3) the symptomatic to inapparent (S:I) ratio is an epidemiologic
correlate for heterologous protective immunity or enhancement
and may be a correlate for vaccine efficacy; (4) the time from last
infection determines the S:I ratio and provides evidence of a half-
life of heterologous protective immunity, which may affect the
observed efficacy in DENV vaccines depending on the time point
efficacy is measured; (5) there is a high degree of temporal and
spatial genetic diversity in the DENVs reinforcing the need for
a tetravalent DENV vaccine but also consideration for the need
of genotypic-specific protection as well; (6) changing population
dynamics and viral evolution with older individuals becoming
infected suggest that immunosenescence and potential viral escape
mutants should be considered when formulating DENV vaccines.
PROSPECTIVE COHORT STUDIES
Prospective cohort studies on DENV transmission; the surveil-
lance of a select group of individuals over time for DENV infec-
tion, are an invaluable source of information on the incidence of
infection, viral, and host factors that lead to subclinical infection
or severe disease, and understanding the full burden of DENV
infection. For testing DENV vaccines, they are essential in deter-
mining the true efficacy of a vaccine. Table 1 is a summary of
the published prospective dengue cohort studies to date. The first
prospective cohort study was conducted in Rayong, Thailand in
January 1980 among children who were sampled from schools
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Rayong, Thailand (2) 1,056 4–14 1980–1981 39.4 n/ab 0.7% 0.7% n/a
Bangkok, Thailand (3) 1,757 4–16 1980–1981 11.8 0.7% 0.4% 0.4% 1:8
Yangon, Myanmar (4) 12,489 1–9 1984–1988 5.1 n/a 0.3% 0.2% n/a
Yogyakarta, Indonesia (5) 1,837 4–9 1995–1996 29.2 0.6% 0.4% 0.4% n/a
Kamphaeng Phet I, Thailand (6) 2,119 7–11 1998–2002 7.3 3.9% 1.0% 0.6% 1:0.9
Iquitos, Peru (7) 2,300 5–20 1999–2005 34.5 n/a n/a n/a n/a
West Java, Indonesia (8) 2,536 18–66 2000–2002 7.4 1.8% 0.1% 0.1% 1:3
Managua, Nicaragua (9, 10) 1,186 4–16 2001–2002 9.0 0.85% n/a n/a 1:13–1:6
Maracay, Venezuela (11) 981 5–13 2001–2002 16.9 n/a n/a n/a n/a
Kamphaeng Phet II, Thailand (12) 2,095 4–16 2004–2006 6.7 2.2% 0.5% 0.1% 1:3.0
Ratchaburi, Thailand (13, 14) 3,015 3–11 2006–2009 3.6 3.6% 1.6% 0.3% n/a
Managua, Nicaragua (10) 3,800 2–9 2004–2010 9.0 0.85% n/a n/a 1:13–1:6




1,500 2–14 2010–2011 11.4 n/a n/a n/a n/a
aNumber in cohort tested for dengue antibody (incidence denominator).
bn/a, not available; not provided in the published paper.
and households (2). Pre- and post-epidemic cohort blood samples
determined that the incidence of dengue infection in 251 seroneg-
ative children was 39.4%. The average incidence of hospitalized
dengue was 0.7%. Of the shock syndrome cases admitted to the
hospital, the major risk factor for severe infection was secondary
infection. The Rayong study was the first to establish the high bur-
den of dengue illness in Thailand, the association of secondary
dengue infections with severe dengue illness, the circulation of
all four DENV serotypes and the preponderance of one specific
serotype in a given epidemic year, and the importance of sequen-
tial dengue serotypes in producing shock syndrome. Despite the
variation in incidence amongst the prospective studies listed in
Table 1, the incidence of severe hospitalized disease is remark-
able consistent, all countries where they were conducted have a
high burden of DENV infection and >80% of severe infections
are associated with subsequent DENV infections after a primary
infection.
The second prospective study was a 2-year (1980–1981) school-
based study involving 1,757 children, ages 4–16 years, in Bangkok,
Thailand (3). This was the first study to use active surveillance
using school absence as an indicator of potential illness. Anti-
body titer revealed that 50% of the enrolled students had evidence
of dengue antibody, likely indicative of a DENV infection expe-
rienced prior to the age of 7 years, and the first to demonstrate
that even at this young age the population is already highly
flavivirus antibody experienced. Most (87%) of the students
who became infected during the study period were asympto-
matic as determined by lack of clinical illness. Important study
findings were an incidence in dengue-naïve participants of 6.3%,
in dengue-experienced participants an incidence of 5.5% and
among symptomatic infected children a hospitalization rate of
53%. The symptomatic-to-asymptomatic ratio of DENV infec-
tion was 1:8. This study confirmed the importance of subsequent
DENV infection as a risk factor for severe infection with an odds
ratio for developing DHF in participants with pre-existing dengue
immunity ≥6.5. The importance of this prospective study was as
the first study to determine the full burden of DENV infection
within a cohort, the incidence of infection and the relationship of
pre-existing DENV immunity to dengue disease severity.
In the last decade a number of prospective cohort studies on
DENV transmission have been performed adding to our knowl-
edge on DENV incidence and risk factors for severe infection.
These include an ongoing study in Iquitos, Peru (the first in the
Americas), one in Indonesia (the first in adults), an ongoing study
in Nicaragua, studies in Venezuela,Vietnam, Malaysia, Philippines,
Vietnam, and ongoing studies in Kamphaeng Phet, Thailand.
INCIDENCE RATES WILL SUPPORT PHASE III EFFICACY
STUDIES THOUGH A HIGH DEGREE OF TEMPORAL AND
SPATIAL DIVERSITY IN INCIDENCE OCCURS REQUIRING
CONSIDERATION IN CHOOSING POPULATIONS
The prospective studies from both the America and Asia have
demonstrated a high burden of DENV infection and incidence
rates that clearly support economically feasible DENV vaccine effi-
cacy studies. With an average incidence of symptomatic DENV
infection of 2%, a sample size calculation using an 80% efficacy
of the vaccine, an alpha value of 0.05, power of 0.8, will require a
total sample size of vaccinated and controls of 1,452 volunteers.
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Studies in Iquitos, Peru and in Kamphaeng Phet, Thailand (ref-
erenced in Table 1) demonstrated the heterogeneity of DENV
incidence and serotype-specific transmission spatially and tem-
porally and illustrated elegantly in schools in Kamphaeng Phet,
Thailand. In Kamphaeng Phet, dengue incidence and serotype-
specific transmission was cyclical in each school, with relatively
mild years followed by more severe years. A proportion of schools
had a severe dengue year while other schools a short distance
away had less severe dengue. Similarly, one school would have a
DENV-2 outbreak and another a short distance away a DENV-3
outbreak. The diversity of incidence both spatially and tempo-
rally is an important observation from these studies in designing
dengue vaccine efficacy studies and in estimating and choosing the
population and geographic location required to assess statistical
efficacy.
PRE-EXISTING SEROTYPE-SPECIFIC NEUTRALIZING
ANTIBODY DOES NOT PROTECT AGAINST INFECTION
SUGGESTS THAT OUR CURRENT ASSAYS TO MEASURE
NEUTRALIZING ANTIBODY IS NOT A CORRELATE FOR
PROTECTION
Historically and currently, DENV neutralizing antibody has been
a serologic biomarker to measure previous and current DENV
serotype-specific infection (1, 17, 18). The role of homotypic and
heterotypic antibody as a marker of immunity was first described
in studies performed by Sabin in the 1940s in human volun-
teers (19, 20). The concept as demonstrated was that following a
serotype-specific DENV infection, homotypic antibody develops
to that specific serotype that last life-long and becomes a biomarker
that indicates previous infection to that serotype and thus durable
immunity. Heterotypic, cross-reactive antibody to other DENV
serotypes following a serotype-specific infection also develops, is
transient, and may modify disease severity when infected with
another serotype. The development of the plaque reduction neu-
tralization titer (PRNT) assay and its variation for DENV became
a relatively high-throughput assay to measure this biomarker for
previous and current serotype-specific protection (17). As such
it has evolved to be an important biomarker to measure DENV
vaccine performance in pre-clinical and clinical DENV vaccine
trials. We have demonstrated that this assay has a high degree
of variability in its performance depending on the cell lines and
prototype viruses used and the detection of heterotypic neutral-
izing antibody creates confusion in its interpretation of whether
an individual is protected or not from a specific serotype (21).
In the Kamphaeng Phet cohort studies, the active surveillance for
infection and analysis of archived sera from infected individuals
allowed the examination of serotype-specific PRNT antibody just
prior to severe DENV infection (22). What was demonstrated was
the observation that individuals hospitalized for severe serotype-
specific DENV had detectable PRNT titers to that serotype using
either prototype DENV and to their own isolated virus approxi-
mately 6 months prior to infection. The implication of this finding
was that the PRNT was not an adequate biomarker for serotype-
specific protection. Ten years later this finding was reiterated
during the vaccine efficacy studies of the ChimeriVax vaccine (1).
Despite high levels of DENV-2 neutralizing antibody as detected
by PRNT, only 9.2% were protected. These findings highlight the
need for the development of biomarkers that are highly predic-
tive of serotype-specific DENV protection and currently a major
obstacle in the development of DENV vaccines.
SYMPTOMATIC TO INAPPARENT RATIO IS AN
EPIDEMIOLOGIC CORRELATE FOR HETEROLOGOUS
PROTECTIVE ANTIBODY AND MAY BE A CORRELATE FOR
VACCINE EFFICACY
The original Bangkok prospective study demonstrated the full
burden of DENV infection, documented the occurrence of sub-
clinical infection and introduced the concept of the S:I ratio (3).
In the Kamphaeng Pet cohort studies, we have demonstrated that
the S:I ratio is not a fixed variable but there is a variance in the
ratio that varies spatially and temporally (6). This ratio was fluid
with schools experiencing more symptomatic disease, high S:I
ratio, than other schools which shifted the following year where
schools had more subclinical infections, lower S:I ratios, while
other schools experienced high S:I ratios. This variation in the S:I
ratio when analyzed closely is not a random event but occurs in a
cyclic pattern with one school having a high S:I ratio, more symp-
tomatic infection, followed in the same school by years of lower
S:I ratios, less symptomatic infection. This pattern was reflected
at the individual school level and also as a population as a whole.
An explanation of this variance is that the S:I ratio is an epi-
demiologic correlate for an undercurrent of heterotypic protective
immunity that may not prevent infection but may modify disease
severity. At an individual level what this implies is that following
a serotype-specific infection there is the generation of heterotypic
antibody that modulates severity of infection that fades with time.
At the same time there is a heterotypic enhancing antibody that
can influence the production of more severe dengue infection.
Expanding from an individual level, this effect applies to local
populations such as schools, villages and to the population as a
whole and will be discussed in more detail in the next section.
The data suggest that the S:I ratio is an epidemiologic correlate
for this protective or disease enhancing heterotypic antibody and
reflects the time-dependant flavivirus experience of a population.
For DENV vaccine studies, the S:I ratio may be a very important
correlate of the vaccine’s ability to confer heterotypic protection
or enhancement of disease severity and potentially an important
efficacy correlate to follow over time in a population.
TIME FROM LAST INFECTION DETERMINES THE S:I RATIO
AND PROVIDES EVIDENCE OF A HALF-LIFE OF
HETEROLOGOUS PROTECTIVE IMMUNITY WHICH MAY
AFFECT THE OBSERVED EFFICACY IN DENV VACCINES
DEPENDING ON THE TIME POINT EFFICACY IS MEASURED
As discussed, the S:I ratio in a population over time is an epidemi-
ologic correlate that reflects an undercurrent of both heterotypic
protective and enhancing immunity that is time-dependant. We
and others have demonstrated that the time from last infection
determines the S:I ratio and that there is a measurable half-life
of heterologous protective immunity (23, 24). This was elegantly
demonstrated in the Kamphaeng Phet cohort studies and recently
published (23). Data from the prospective cohort studies were
analyzed for subclinical and symptomatic DENV infections in
schoolchildren from 1998 to 2007. Children who experienced one
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or more DENV infection were selected as the population for analy-
sis (2,169 person-years of follow-up). Demonstrated from the
analysis was a shorter time interval between infections was associ-
ated with subclinical infection in children who were seronegative
for DENV at enrollment; seronegative being an important pre-
existing condition to document primary to secondary infections
as compared to the more complicated second to third infections.
This time interval was an average of 1.6 years from first infection
that resulted in a subclinical infection, 1.9 years for symptomatic
dengue fever (DF), and 2.6 years for the onset of severe hospitalized
dengue hemorrhagic fever (DHF). These findings indicate that
there is a window of cross-protection following DENV infection
that last approximately 1.6 years following infection. The implica-
tions of these findings for DENV vaccine efficacy studies are subtle
but important. The goal for a tetravalent DENV vaccine is to con-
fer durable tetravalent DENV immunity and protection against
severe illness. If one serotype in the DENV tetravalent formulation
in particular induces a brisk immune response, the results from
the prospective cohort studies would suggest that there will be
heterotypic protective immunity from that one serotype to other
serotypes conferring tetravalent protection that lasts for 1.6 years.
If true, then measuring efficacy at 1 year following vaccination as
the most recent DENV vaccine trial did, would not be a true mea-
surement of tetravalent protection. A more appropriate efficacy
time point would be at least 3 years following vaccination as a
true measurement of efficacy. This of course would mean a longer
duration of observation of the population following vaccination
and cost of the study.
THERE IS A HIGH DEGREE OF TEMPORAL AND SPATIAL
GENETIC DIVERSITY IN THE DENVs REINFORCING THE NEED
FOR A TETRAVALENT DENV VACCINE BUT ALSO
CONSIDERATION FOR THE NEED OF GENOTYPIC-SPECIFIC
PROTECTION AS WELL
It is thought that the DENV transmission evolved into four distinct
serotypes approximately 1,000 years ago and each of these four
serotypes emerged into a cycle of transmission between humans
and its mosquito vector approximately 125–320 years ago (25, 26).
Phylogenetic analysis suggests that the DENVs are rapidly evolv-
ing with major clade replacements and genetic shifts occurring
in populations endemic for DENV (25–28). Asia has been pivotal
in the evolution of DENV as the location of the first cases of the
more severe form of DENV infection, DHF, which made its first
appearance in the 1950s first in the Philippines then in Thailand
(29). The current Asian genotypes of each serotype are considered
more severe, result in more severe dengue illness, than the Amer-
ican genotypes (30). Evidence suggests that DENV circulation in
Asia due to its population growth and urbanization, high vector
burden, and high level of pre-existing flavivirus seroprevalence,
contribute to the increase in genetic diversity which is estimated
as increasing at a factor between 14 and 20 in the last 30 years (31).
The overall impression of DENV evolution in Asia is the active
transmission of viruses in individuals who are highly flavivirus
antibody experienced causing evolutionary pressure on the virus
to evolve to escape and utilize pre-existing flavivirus immunity. By
its nature the current evolving DENVs are adept at escaping het-
erologous neutralizing antibody and using it as a means to attain
high viral load levels and more severe disease through antibody
enhancement.
To understand the evolution and phylogeography of DENV, the
prospective cohort studies in Kamphaeng Phet have been isolating
and sequencing DENVs from individuals in specific geographic
areas and over time. In ongoing studies, viruses are isolated and
through the use of global positioning system (GPS) the exact geo-
graphic position located allowing specific spatial and temporal
analysis. Analysis of isolated viruses demonstrated diverse viral
genetic variation in both time and space in the Kamphaeng Phet
population with multiple viral lineages circulating within individ-
ual schools and villages (32). This implies that there is frequent
gene flow of DENV into this microenvironment as individuals
move from major urban areas into smaller village. At the microen-
vironment level, there was clustering of specific viral genotypes
within individual schools that are highly conserved from year
to year and evidence of frequent viral gene flow among schools
closely related in space and time. These results suggest that there is
a combination of frequent viral migration into Kamphaeng Phet
coupled with population subdivisions of conserved viruses that
shape the genetic diversity of DENV at a local and population
scale. Taken together is a picture of a virus that is evolving rapidly,
spread by population movement, and due to the restricted flight
of the vector, genetically conserved at a microenvironment level.
For a DENV vaccine these findings have many implications with
the most important is that the current vaccines using historical
prototype viruses collected in the 1980s may no longer provide the
protection to current circulating DENV genotypes and raises the
question if protection needs to be both serotype and genotype spe-
cific. This question was raised during the ChimeriVax vaccine trial
where the DENV-2 vaccine strain did not match the circulating
wild-type DENV-2 and failed to produce protection (1).
CHANGING POPULATION DYNAMICS AND VIRAL
EVOLUTION WITH OLDER INDIVIDUALS BECOMING
INFECTED SUGGEST THAT IMMUNOSENESCENCE AND
POTENTIAL VIRAL ESCAPE MUTANTS SHOULD BE
CONSIDERED WHEN FORMULATING DENV VACCINES
Dengue illness in endemic countries is considered to be primar-
ily a pediatric disease due to the high degree of transmission
and infection that occurs at a young age. Adults are considered
highly flavivirus experienced and thus protected from subsequent
dengue illness. For this reason, the prospective cohort studies have
largely been performed in pediatric populations and illness cri-
teria of severity of disease developed in pediatric populations. In
our own cohort studies, we have noted that the age of sympto-
matic DENV infection has been increasing slowly over the last
decade by a median increase of 2–4 years. This has been reflected
in Thailand as a whole and interestingly in the rest of Southeast
Asia (33). An analysis and mathematical modeling of this phe-
nomenon was performed on data from each of the 72 provinces of
Thailand (33). What was described was that the force of infection
has declined by 2% each year with the strongest predictor of this
change the median age of the population, which was reflective of
the changing demographics of the population. The authors’ con-
clusion was that lower birth and death rates decrease the flow of
susceptible individuals into the population and thereby increase
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the longevity of immune individuals. For a DENV vaccine, the
implications are despite the decrease in the force of infection the
critical vaccination fraction has not changed declining from 85 to
80% (2). A key point in this argument however is the longevity
of immune individuals and if protection is life-long. Recently, in
our own studies in Kamphaeng Phet we have been documenting
a large number of adults who are older than 50 years of age with
one 80-year old hospitalized with severe DENV infection. These
are individuals who have never moved from Kamphaeng Phet, a
highly endemic region for DENV, and defy statistical probability of
never having been infected by one or more DENVs in their previ-
ous experience. This is under active investigation but does suggest
that the aging immune system, immunosenescence, might be a fac-
tor in older individuals becoming ill from DENV infection or, and
particularly worrisome, that the current strains/genotypes have
evolved as escape mutants and individuals are no longer protected
from current wild-type DENV strains/genotypes despite infec-
tion from another genotype but same serotype in the past. This
as noted in the previous section has implications on the current
DENV vaccine candidates and whether their vaccine prototype
strains/genotypes are applicable to current circulating genotypes.
SUMMARY
The prospective studies have been invaluable in increasing our
understanding on the epidemiology and pathogenesis of this glob-
ally important virus and disease. Discussed are important lessons
learned from these studies that have direct application to current
DENV vaccine development and testing as they move forward in
their regulatory development to a licensed vaccine. Identified are
critical issues that are challenges for the development of an effec-
tive tetravalent DENV vaccine. Additional research is needed to
address these areas that are critical to vaccine testing and evalua-
tion. Expanding cohort studies to include those countries where
dengue is inadequately characterized is critical for us to further
understand the unique viral and host factors that contribute to
differences in dengue risk and vaccine response.
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